1
|
Dong X. Mechanisms affecting the biopharmacological properties of saffron active ingredients based on anti-inflammatory activity. Biotechnol Genet Eng Rev 2024; 40:540-561. [PMID: 36946493 DOI: 10.1080/02648725.2023.2184965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2023] [Accepted: 02/18/2023] [Indexed: 03/23/2023]
Abstract
To explore the mechanisms affecting the biopharmacological properties of the active components of saffron. Ultrasonic extraction technique was applied to extract the active components from safflower materials and combined with molecular docking technique to screen four safflower anti-inflammatory active components, naiophenol-3-0-rutinoside, kaempferol-3-O-glucoside, quercetin and lignan. In order to understand the mechanism of the influence of its biopharmaceutical properties, the changes of the solubility and permeability parameters of the anti-inflammatory active components of safflower were obtained by using the classical shaking bottle method and the body enteric irrigation method. The compound environment had a great influence on the solubility of single active ingredient. The calculated results of the dose number of all ingredients were greater than 1, and the solubility properties were all high solubility. The absorption parameters and osmotic coefficients of kaempferol-3-O-glucoside and lignan varied insignificantly under different concentration conditions, while each osmotic coefficient of kaempferol-3-O-rutinoside and quercetin showed a positive proportional decreasing trend. In addition, the osmotic coefficients of the three components except kaempferol-3-O-glucoside did not change with environmental changes, and the overall anti-inflammatory active ingredient absorption mechanisms included both passive diffusion and active transport. The two biopharmaceutical properties of the solubility and permeability of the active ingredients of Safflower can be changed under the influence of the application environment and drug concentration. In the pharmaceutical process, the preparation means can be optimized from this aspect to achieve the purpose of improving the clinical efficacy of Safflower anti-inflammatory drugs.
Collapse
Affiliation(s)
- Xiangmin Dong
- West China School of Pharmacy, Sichuan University, Chengdu, Sichuan, China
| |
Collapse
|
2
|
Zhang Q, Chen X, Palen K, Johnson B, Bui D, Xiong D, Pan J, Hu M, Wang Y, You M. Cancer chemoprevention with PV-1, a novel Prunella vulgaris-containing herbal mixture that remodels the tumor immune microenvironment in mice. Front Immunol 2023; 14:1196434. [PMID: 38077406 PMCID: PMC10704350 DOI: 10.3389/fimmu.2023.1196434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Accepted: 07/20/2023] [Indexed: 12/18/2023] Open
Abstract
The herb Prunella vulgaris has shown significant immune-stimulatory and anti-inflammatory effects in mouse models. Here, the effects of a novel Prunella vulgaris-containing herbal mixture, PV-1, were examined in several mouse models for cancer, including chemically induced models of lung and oral cancers as well as syngraft models for lung cancer and melanoma. PV-1, consisting of extracts from Prunella vulgaris, Polygonum bistorta, Sonchus brachyotus and Dictamnus dasycarpus, exhibited no toxicity in a dose escalation study in A/J mice. PV-1 significantly inhibited mouse lung tumor development induced by the lung carcinogens vinyl carbamate and benzo[a]pyrene. PV-1 also hindered the induction of oral squamous cell carcinomas in C57BL/6 mice caused by 4-nitroquinoline-1-oxide. Flow cytometry analysis showed that PV-1 increased the numbers of CD8+ tumor-infiltrating lymphocytes (TILs) and increased the production of granzyme B, TNF-α, and IFN-γ by CD8+ TILs. PV-1 also suppressed granulocytic myeloid-derived suppressor cell numbers (g-MDSCs) and improved the anti-cancer activity of anti-PD-1 immunotherapy. These results indicate that PV-1 remodels the tumor immune microenvironment by selectively inhibiting g-MDSCs and increasing CD8+ TILs within tumors, resulting in decreased immune suppression and enhanced cancer chemopreventive efficacy.
Collapse
Affiliation(s)
- Qi Zhang
- Center for Cancer Prevention, Dr. Mary and Ron Neal Cancer Center, Houston Methodist Research Institute, Houston, TX, United States
| | - Xu Chen
- Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, WI, United States
| | - Katie Palen
- Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, United States
| | - Bryon Johnson
- Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, United States
| | - Dinh Bui
- College of Pharmacy, University of Houston, Houston, TX, United States
| | - Donghai Xiong
- Center for Cancer Prevention, Dr. Mary and Ron Neal Cancer Center, Houston Methodist Research Institute, Houston, TX, United States
| | - Jing Pan
- Center for Cancer Prevention, Dr. Mary and Ron Neal Cancer Center, Houston Methodist Research Institute, Houston, TX, United States
| | - Ming Hu
- College of Pharmacy, University of Houston, Houston, TX, United States
| | - Yian Wang
- Center for Cancer Prevention, Dr. Mary and Ron Neal Cancer Center, Houston Methodist Research Institute, Houston, TX, United States
| | - Ming You
- Center for Cancer Prevention, Dr. Mary and Ron Neal Cancer Center, Houston Methodist Research Institute, Houston, TX, United States
| |
Collapse
|
3
|
Jiang X, Yang X, Shi Y, Long Y, Su W, He W, Wei K, Miao J. Maackiain inhibits proliferation and promotes apoptosis of nasopharyngeal carcinoma cells by inhibiting the MAPK/Ras signaling pathway. Chin J Nat Med 2023; 21:185-196. [PMID: 37003641 DOI: 10.1016/s1875-5364(23)60420-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2022] [Indexed: 04/03/2023]
Abstract
Nasopharyngeal carcinoma (NPC) is the third most common malignancy with a high recurrence and metastasis rate in South China. Natural compounds extracted from traditional Chinese herbal medicines have been developed and utilized for the treatment of a variety of cancers with modest properties and slight side effects. Maackiain (MA) is a type of flavonoid that was first isolated from leguminous plants, and it has been reported to relieve various nervous system disorders and exert anti-allergic as well as anti-inflammatory effects. In this study, we demonstrated that MA inhibited proliferation, arrested cell cycle and induced apoptosis in nasopharyngeal carcinoma CNE1 and CNE2 cells in vitro and in vivo. The expression of the related proteins associated with these processes were consistent with the above effects. Moreover, transcriptome sequencing and subsequent Western blot experiments revealed that inhibition of the MAPK/Ras pathway may be responsible to the anti-tumor effect of MA on NPC cells. Therefore, the effects of MA and an activator of this pathway, tertiary butylhydroquinone (TBHQ), alone or combination, were investigated. The results showed TBHQ neutralized the inhibitory effects of MA. These data suggest that MA exerts its anti-tumor effect by inhibiting the MAPK/Ras signaling pathway and it has the potential to become a treatment for patients with NPC.
Collapse
Affiliation(s)
- Xing Jiang
- College of Pharmacy, Guangxi Medical University, Nanning 530021, China; Guangxi Key Laboratory of Medicinal Resources Protection and Genetic Improvement/Guangxi Engineering Research Center of TCM Resource Intelligent Creation, Guangxi Botanical Garden of Medicinal Plants, Nanning 530023, China; The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, China
| | - Xiaonan Yang
- Guangxi Key Laboratory of Medicinal Resources Protection and Genetic Improvement/Guangxi Engineering Research Center of TCM Resource Intelligent Creation, Guangxi Botanical Garden of Medicinal Plants, Nanning 530023, China.
| | - Yanxia Shi
- College of Pharmacy, Guangxi Medical University, Nanning 530021, China; Guangxi Key Laboratory of Medicinal Resources Protection and Genetic Improvement/Guangxi Engineering Research Center of TCM Resource Intelligent Creation, Guangxi Botanical Garden of Medicinal Plants, Nanning 530023, China
| | - Yan Long
- College of Pharmacy, Guangxi Medical University, Nanning 530021, China; Guangxi Key Laboratory of Medicinal Resources Protection and Genetic Improvement/Guangxi Engineering Research Center of TCM Resource Intelligent Creation, Guangxi Botanical Garden of Medicinal Plants, Nanning 530023, China
| | - Wenqing Su
- Guangxi Key Laboratory of Medicinal Resources Protection and Genetic Improvement/Guangxi Engineering Research Center of TCM Resource Intelligent Creation, Guangxi Botanical Garden of Medicinal Plants, Nanning 530023, China; College of Pharmacy, Youjiang Medical University for Nationalities, Baise 533000, China
| | - Wendong He
- Guangxi Key Laboratory of Medicinal Resources Protection and Genetic Improvement/Guangxi Engineering Research Center of TCM Resource Intelligent Creation, Guangxi Botanical Garden of Medicinal Plants, Nanning 530023, China; Department of Pharmacy, Guangxi Medical University Affiliated Tumor Hospital, Nanning 530021, China
| | - Kunhua Wei
- Guangxi Key Laboratory of Medicinal Resources Protection and Genetic Improvement/Guangxi Engineering Research Center of TCM Resource Intelligent Creation, Guangxi Botanical Garden of Medicinal Plants, Nanning 530023, China
| | - Jianhua Miao
- College of Pharmacy, Guangxi Medical University, Nanning 530021, China; Guangxi Key Laboratory of Medicinal Resources Protection and Genetic Improvement/Guangxi Engineering Research Center of TCM Resource Intelligent Creation, Guangxi Botanical Garden of Medicinal Plants, Nanning 530023, China.
| |
Collapse
|
4
|
Bui D, McWilliams LA, Wu L, Zhou H, Wong SJ, You M, Chow DSL, Singh R, Hu M. Pharmacokinetic Basis for Using Saliva Matrine Concentrations as a Clinical Compliance Monitoring in Antitumor B Chemoprevention Trials in Humans. Cancers (Basel) 2022; 15:cancers15010089. [PMID: 36612086 PMCID: PMC9817974 DOI: 10.3390/cancers15010089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2022] [Revised: 12/15/2022] [Accepted: 12/19/2022] [Indexed: 12/28/2022] Open
Abstract
This study reports the first clinical evidence of significantly high secretion of matrine in a multi-component botanical (Antitumor B, ATB) into human saliva from the systemic circulation. This is of high clinical significance as matrine can be used as a monitoring tool during longitudinal clinical studies to overcome the key limitation of poor patient compliance often reported in cancer chemoprevention trials. Both matrine and dictamine were detected in the saliva and plasma samples but only matrine was quantifiable after the oral administration of ATB tablets (2400 mg) in 8 healthy volunteers. A significantly high saliva/plasma ratios for Cmax (6.5 ± 2.0) and AUC0-24 (4.8 ± 2.0) of matrine suggested an active secretion in saliva probably due to entero-salivary recycling as evident from the long half-lives (t1/2 plasma = 10.0 ± 2.8 h, t1/2 saliva = 13.4 ± 6.9 h). The correlation between saliva and plasma levels of matrine was established using a population compartmental pharmacokinetic co-model. Moreover, a species-relevant PBPK model was developed to adequately describe the pharmacokinetic profiles of matrine in mouse, rat, and human. In conclusion, matrine saliva concentrations can be used as an excellent marker compound for mechanistic studies of active secretion of drugs from plasma to saliva as well as monitor the patient's compliance to the treatment regimen in upcoming clinical trials of ATB.
Collapse
Affiliation(s)
- Dinh Bui
- College of Pharmacy, University of Houston, Houston, TX 77204, USA
| | | | - Lei Wu
- College of Pharmacy, University of Houston, Houston, TX 77204, USA
| | | | - Stuart J. Wong
- Department of Neoplastic Diseases, Medical College of Wisconsin, Milwaukee, WI 53226, USA
| | - Ming You
- Houston Methodist, Houston, TX 77030, USA
| | - Diana S.-L. Chow
- College of Pharmacy, University of Houston, Houston, TX 77204, USA
| | - Rashim Singh
- College of Pharmacy, University of Houston, Houston, TX 77204, USA
- Correspondence: (R.S.); (M.H.)
| | - Ming Hu
- College of Pharmacy, University of Houston, Houston, TX 77204, USA
- Correspondence: (R.S.); (M.H.)
| |
Collapse
|